ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp (TTI)

0.65
0.01
(1.56%)
Closed February 13 4:00PM
Advanced chart

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.65
Bid
0.61
Ask
0.67
Volume
500
0.65 Day's Range 0.65
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.64
Open
0.65
Last Trade
500
@
0.65
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
44,570,000
Dividend Yield
-
PE Ratio
-1.95
Earnings Per Share (EPS)
-0.11
Revenue
-
Net Profit
-5.03M

About Thiogenesis Therapeutics Corp

Sector
Pharmaceutical Preparations
Industry
Unit Inv Tr, Closed-end Mgmt
Headquarters
Toronto, Ontario, Can
Founded
2022
Thiogenesis Therapeutics Corp is listed in the Pharmaceutical Preparations sector of the TSX Venture Exchange with ticker TTI. The last closing price for Thiogenesis Therapeutics was $0.64. Over the last year, Thiogenesis Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Thiogenesis Therapeutics currently has 44,570,000 shares outstanding. The market capitalization of Thiogenesis Therapeutics is $28.52 million. Thiogenesis Therapeutics has a price to earnings ratio (PE ratio) of -1.95.

TTI Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

TTI - Frequently Asked Questions (FAQ)

What is the current Thiogenesis Therapeutics share price?
The current share price of Thiogenesis Therapeutics is $ 0.65
How many Thiogenesis Therapeutics shares are in issue?
Thiogenesis Therapeutics has 44,570,000 shares in issue
What is the market cap of Thiogenesis Therapeutics?
The market capitalisation of Thiogenesis Therapeutics is CAD 28.52M
What is the 1 year trading range for Thiogenesis Therapeutics share price?
Thiogenesis Therapeutics has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the PE ratio of Thiogenesis Therapeutics?
The price to earnings ratio of Thiogenesis Therapeutics is -1.95
What is the reporting currency for Thiogenesis Therapeutics?
Thiogenesis Therapeutics reports financial results in CAD
What is the latest annual profit for Thiogenesis Therapeutics?
The latest annual profit of Thiogenesis Therapeutics is CAD -5.03M
What is the registered address of Thiogenesis Therapeutics?
The registered address for Thiogenesis Therapeutics is 4 KING STREET WEST, STE. 401, TORONTO, ONTARIO, M5H 1B6
What is the Thiogenesis Therapeutics website address?
The website address for Thiogenesis Therapeutics is www.thiogenesis.com
Which industry sector does Thiogenesis Therapeutics operate in?
Thiogenesis Therapeutics operates in the UNIT INV TR, CLOSED-END MGMT sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JAEG.HJaeger Resources Corp
$ 0.015
(200.00%)
6k
CTNClass A Common Shares
$ 0.015
(200.00%)
14k
CFA.HClear Gold Resources Inc
$ 0.025
(150.00%)
1,000
GHR.HGolden Harp Resources Inc
$ 0.095
(137.50%)
1.5k
ADEAdex Mining Inc
$ 0.01
(100.00%)
3.44M
NFD.ANorthfield Capital Corporation
$ 4.60
(-77.00%)
831
DMDataMetrex AI Limited
$ 0.005
(-50.00%)
189k
SMAR.PSmartset Services Inc
$ 0.04
(-42.86%)
13k
NZNew Zealand Energy Corp
$ 0.50
(-37.50%)
20.51k
OEC.HOracle Energy Corp
$ 0.045
(-35.71%)
80.39k
DGODurango Resources Inc
$ 0.10
(33.33%)
5.18M
ADEAdex Mining Inc
$ 0.01
(100.00%)
3.44M
KGSKingman Minerals Ltd
$ 0.115
(9.52%)
2.31M
QUISQuisitive Technology Solutions Inc
$ 0.56
(0.00%)
2.07M
LUCALuca Mining Corp
$ 1.12
(12.00%)
1.98M

TTI Financials

Financials

TTI Discussion

View Posts
CommodityCoverage CommodityCoverage 16 hours ago
Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced that its common shares are now trading on the OTCQX Best Market under the ticker symbol TTIPF, increasing visibility for U.S. investors: https://www.newsfilecorp.com/release/240489/Thiogenesis-Announces-Commencement-of-OTCQX-Trading-in-the-U.S

Targeting multi-billion-dollar market potential, the clinical-stage biotechnology company recent received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS), a rare inherited mitochondrial disorder with no approved treatments: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/
👍️0
CommodityCoverage CommodityCoverage 2 days ago
With strong regulatory positioning, expanding patent coverage, and a multi-billion-dollar market potential, Thiogenesis Therapeutics (TTI.v TTIPF) is advancing into Phase II clinical trials for its lead drug TTI-0102 as a potential treatment for MELAS: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

TTI-0102, leverages sustained-release cysteamine to enhance mitochondrial function and combat oxidative stress and is poised to be a breakthrough treatment not only for MELAS but additionally for Leigh syndrome, and pediatric MASH— all devastating diseases with no approved therapies and urgent unmet medical needs.
👍️0
CommodityCoverage CommodityCoverage 3 days ago
Thiogenesis Therapeutics (TTI.v TTIPF) is gearing up for Phase II clinical trials in 2025 with a cutting-edge treatment targeting MELAS, Leigh syndrome, and pediatric MASH—all diseases with no approved treatments and massive unmet medical needs.

Their lead drug, TTI-0102, delivers sustained-release cysteamine, a key player in mitochondrial health and oxidative stress reduction. With regulatory advantages, expanding patent protection, and a billion-dollar market potential, is this an overlooked opportunity? Full DD & latest progress here: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/
👍️0
CommodityCoverage CommodityCoverage 7 days ago
Set to begin shortly, Thiogenesis Therapeutics (TTI.v) will be commencing a multi-country, multi-center trial in France and the Netherlands to evaluate the safety, tolerability, and efficacy of its TTI-0102 as a potential treatment for MELAS, a rare mitochondrial disorder with no approved therapies: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/
👍️0
CommodityCoverage CommodityCoverage 1 week ago
Thiogenesis Therapeutics (TTI.v) has received final regulatory clearance from the European Medicines Agency (EMA) to proceed with its Phase 2 clinical trial for TTI-0102, a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS): https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

The multi-country, multi-center trial in France and the Netherlands will evaluate the safety, tolerability, and efficacy of oral TTI-0102 in 12 patients over six months, with an interim analysis at three months.

Notably, TTI-0102 is a prodrug designed to increase intracellular glutathione and taurine, addressing key deficiencies in MELAS patients. It improves on earlier thiol-based treatments by offering a longer half-life and fewer side effects. MELAS, a rare mitochondrial disorder affecting 4.4 per 100,000 people, leads to seizures, fatigue, and muscle weakness, with oxidative stress and taurine deficiency as potential treatment targets.
👍️0
CommodityCoverage CommodityCoverage 1 week ago
Gearing up for Phase II clinical trials in 2025 for TTI-0102, a next-generation treatment targeting MELAS, Leigh syndrome, and pediatric MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is a unique clinical-stage biotech company focused on devastating diseases with no approved therapies: https://www.reddit.com/r/Wallstreetbetsnew/comments/1ietya8/thiogenesis_therapeutics_ttiv_ttipf_advancing/

With its innovative sustained-release cysteamine prodrug, streamlined FDA approval pathway, and expanding global patents, Thiogenesis is rapidly advancing toward potentially game-changing treatments for mitochondrial and metabolic disorders.
👍️0
CommodityCoverage CommodityCoverage 1 week ago
Allowing the company to proceed with its multi-center trial in France and the Netherlands, evaluating the safety, tolerability, and efficacy of TTI-0102 in 12 patients over six months, Thiogenesis Therapeutics (TTI.v) has received final regulatory clearance from the European Medicines Agency (EMA) to initiate its Phase 2 clinical trial: https://x.com/StckMasterFlash/status/1883977520837443663

With no approved treatments for MELAS, TTI-0102 offers a novel approach by boosting intracellular glutathione and taurine, addressing key deficiencies in patients. CEO Patrice Rioux highlighted its potential as a viable therapeutic, overcoming limitations of earlier thiol-based drugs. This approval marks a significant step in advancing a promising treatment for an unmet medical need.
👍️0
StockInfo11 StockInfo11 2 weeks ago
Thiogenesis Therapeutics (TTI.v TTIPF) is working to launch Phase II trials in 2025 for TTI-0102, a drug targeting MELAS, Leigh syndrome, and pediatric MASH, all with significant unmet medical needs. TTI-0102 offers sustained release unlike other cysteamine-based treatments, reducing oxidative stress while improving tolerability and bioavailability. More here: https://thiogenesis.webflow.io/investors

*Posted on behalf of Thiogenesis Therapeutics Corp.
👍️0
CommodityCoverage CommodityCoverage 2 weeks ago
Marking a significant mitigation of risk, Thiogenesis Therapeutics (TTI.v) has received EU clearance to commence its Phase 2 clinical trials for TTI-0102 as a potential treatment for MELAS: https://x.com/StckMasterFlash/status/1883977520837443663
 
Set to begin shortly, the trials are a multi-country, multi-center, randomized, double-blind, placebo-controlled study which will be taking place in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS, a condition with no current approved drugs.
👍️0
CommodityCoverage CommodityCoverage 2 weeks ago
With the acceptance of the final regulatory clearance from the European Medicines Agency needed to commence its Phase 2 clinical trial for TTI-0102, a potential treatment for MELAS, Thiogenesis Therapeutics (TTI.v) is set to begin shortly: https://x.com/StckMasterFlash/status/1883977520837443663

The multi-country, multi-center, randomized, double-blind, placebo-controlled study will be taking place in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS, a condition with no current approved drugs.
👍️0
CommodityCoverage CommodityCoverage 2 weeks ago
Today, Thiogenesis Therapeutics (TTI.v) announced that the European Medicines Agency (EMA) has accepted the final regulatory clearance (CTA Part II) needed to commence its Phase 2 clinical trial for TTI-0102, a potential treatment for mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS): https://www.newsfilecorp.com/release/238463/Thiogenesis-Receives-Final-EU-Clearance-of-CTA-to-Initiate-its-Phase-2-Clinical-Trial-in-MELAS

The trial is set to begin shortly, following the activation of clinical trial sites, multi-country, multi-center, randomized, double-blind, placebo-controlled study in France and the Netherlands, assessing the safety, tolerability, pharmacodynamics and efficacy of oral TTI-0102 for the treatment of patients with MELAS. Notably, there are currently no approved drugs for the condition.
👍️0
CommodityCoverage CommodityCoverage 3 weeks ago
Thiogenesis Therapeutics (TTI.v) is a groundbreaking clinical-stage biotech company revolutionizing the treatment of rare mitochondrial dysfunction diseases through its innovative thiol-active compounds: https://x.com/StckMasterFlash/status/1882535523035791823

Its flagship product, TTI-0102, is a prodrug of cysteamine designed to enhance dosing efficiency and minimize side effects that's focused on high-value, rare conditions in a lucrative CAD 9.8 billion global market opportunity.

Advancing its ambitious pipeline with clinical trials for TTI-0102, TTI is set to tackle multiple rare diseases with key milestones including Phase II trials for MELAS and Leigh Syndrome beginning in 2025, with market launches anticipated by 2026-2027 and projected combined peak sales of CAD 4.14 billion.
👍️0
CommodityCoverage CommodityCoverage 3 weeks ago
Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company specializing in thiol-active compounds to treat mitochondrial dysfunction diseases. Its lead product, TTI-0102, is a prodrug of cysteamine designed to improve dosing and reduce side effects and, according to Valuation Lab, with a risk-adjusted net present value (NPV) of CAD 7.5 per share, Thiogenesis offers a significant upside of 1130%: https://x.com/StckMasterFlash/status/1871347807430291939
👍️0
CommodityCoverage CommodityCoverage 3 weeks ago
Targeting three rare diseases and conditions with significant unmet medical needs, Thiogenesis Therapeutics (TTI.v) is represents a significant opportunity in addressing both rare diseases and broader oxidative stress-related challenges with its innovative thiol-based drug TTI-0102: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

Streamlining development by leveraging expedited regulatory pathways in the US and Europe, TTI is able to significantly reduce costs and time to market in an estimated $9.8 billion market opportunity, strongly positioning the company to address critical gaps in the rare disease and antioxidant therapy space.
👍️0
CommodityCoverage CommodityCoverage 3 weeks ago
Clinical stage biotech company Thiogenesis Therapeutics (TTI.v) and its lead product, innovative thiol-based drug TTI-0102, have significant potential, extending beyond addressing rare conditions—it signifies a broader opportunity to revolutionize therapeutic strategies for oxidative stress-related diseases: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

For MELAS, affecting 30,000 individuals in the US, TTI-0102’s ability to mitigate neurological symptoms and stroke-like episodes through mitochondrial support is groundbreaking. In Rett Syndrome, the drug’s promotion of Brain-Derived Neurotrophic Factor (BDNF) could restore nerve cell health and improve motor and cognitive function. Similarly, in pediatric NASH, which impacts 7 million children in the US, TTI-0102’s anti-inflammatory and antioxidant properties offer hope for a condition leading to severe liver complications. With a strong safety profile derived from cysteamine’s pediatric use and a focus on conditions with no existing approved treatments, TTI represents a significant leap forward in addressing both rare diseases and broader oxidative stress-related challenges.
👍️0
CommodityCoverage CommodityCoverage 3 weeks ago
Poised to transform the treatment landscape for rare diseases and conditions with significant unmet medical needs through its innovative thiol-based drug, TTI-0102, Thiogenesis Therapeutics (TTI.v) offers a novel approach to conditions such as MELAS, Rett Syndrome, and pediatric NASH in targeting mitochondrial dysfunction to address the root causes of these diseases, which currently lack approved therapies: https://x.com/StckMasterFlash/status/1880363437781630998

Leveraging expedited regulatory pathways in the US and Europe, TTI can streamline development by referencing existing safety data from similar compounds, significantly reducing costs and time to market. With an estimated $9.8 billion market opportunity, TTI is well-positioned to address critical gaps in the rare disease and antioxidant therapy space and represents a significant leap forward in addressing both rare diseases and broader oxidative stress-related challenges.
👍️0
CommodityCoverage CommodityCoverage 4 weeks ago
Capitalizing on a $9.8 billion market opportunity within the global rare disease and antioxidant therapies space, Thiogenesis Therapeutics (TTI.v) is focused on the development of thiol-based drugs with its lead product TTI-0102: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/    

TTI-0102 leverages its proven safety profile (from cysteamine's pediatric use) to target critical unmet medical needs in MELAS, Rett Syndrome, and NASH. By addressing mitochondrial dysfunction through innovative mechanisms, Thiogenesis presents a promising therapeutic approach for these challenging conditions.
👍️0
CommodityCoverage CommodityCoverage 4 weeks ago
Thiogenesis Therapeutics (TTI.v) is capitalizing on a $9.8 billion market opportunity within the global rare disease and antioxidant therapies space by focusing on the development of thiol-based drugs. Leveraging unique properties to address oxidative stress and mitochondrial dysfunction, TTI's novel lead product offers targeted solutions for unmet medical needs including rare conditions such as MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH : https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

Benefitting from strong regulatory incentives for orphan drug development, TTI's lead product strategically targets both niche and broader applications, positioning the company to drive innovation and deliver significant value in a competitive and high-potential therapeutic area.
👍️0
CommodityCoverage CommodityCoverage 4 weeks ago
Addressing oxidative stress and mitochondrial dysfunction, a $9.8B market with significant unmet medical needs, Thiogenesis Therapeutics (TTI.v) is a rising player in the biotech sector with its novel lead product, TTI-0102, a prodrug of cysteamine designed to improve dosing and reduce side effects: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

By pioneering a platform centered on thiol-based molecules, Thiogenesis aims to deliver groundbreaking therapies for rare disorders and conditions lacking effective treatments. Adding to their appeal, orphan disease therapies often benefit from faster regulatory approval, lower R&D expenditures, and extended periods of market exclusivity.
👍️0
CommodityCoverage CommodityCoverage 4 weeks ago
Emerging biopharmaceutical company, Thiogenesis Therapeutics (TTI.v), is focused on harnessing the therapeutic potential of sulfur-based compounds to address oxidative stress and mitochondrial dysfunction, both of which are implicated in a wide range of diseases: https://www.reddit.com/r/wallstreetsmallcaps/comments/1hxs2xe/biotech_thiogenesis_therapeutics_ttiv_advances/

With an innovative platform leveraging the unique properties of thiol-based molecules, TTI's core focus is on developing novel treatments for orphan diseases and conditions with significant unmet medical needs, targeting a CAD$9.8B market opportunity. Notably, this focus on orphan diseases offers the potential for expedited regulatory pathways, reduced development costs, and attractive market exclusivity periods.
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Targeting a projected global market opportunity of CAD$9.8B, Thiogenesis Therapeutics (TTI.v) is focused on addressing rare conditions including MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH with its lead product, TTI-0102. Poised to make a significant impact on the market, TTI is at the start of a transformational year with multiple trials and regulatory filings expected to provide significant inflection points: https://x.com/StckMasterFlash/status/1877827587096879527
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Interested in a unique opportunity in biotech space? Check out Thiogenesis Therapeutics (TTI.v), a clinical-stage company specializing in thiol-active compounds to treat rare mitochondrial dysfunction diseases, targeting an estimated global market of CAD 9.8 billion:  https://x.com/StckMasterFlash/status/1871347807430291939

With its lead product, TTI-0102—a prodrug of cysteamine designed to improve dosing and reduce side effects—Thiogenesis is poised to make a significant impact in treating conditions like MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH. Notably, Valuation Lab estimates a risk-adjusted net present value of CAD 7.5 per share, translating to a staggering 1130% upside. 
👍️0
StockInfo11 StockInfo11 1 month ago
Thiogenesis Therapeutics (TTI.v) is advancing a drug which addresses MELAS, Leigh Syndrome, Rett Syndrome, and pediatric MASH, with a global peak sales potential of $9.8B as estimated by a recent Valuation Lab report. Taking into account key upcoming catalysts including phase II trials, Valuation Lab gives TTI a sum-of-parts (r)NPV of $7.50/share, well above its current $0.58 share price. Full report: https://www.valuationlab.com/app/download/8229158562/vL+Thiogenesis+Flash+Update+16DEC24.pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.
👍️0
Consequent Consequent 1 month ago
Recommend this post on Thiogenesis Therapeutics Corp. (TTI.v TTIPF) and the development of the drug TTI-0102 which is designed to treat pediatric NASH by releasing cysteamine, a potent antioxidant that can reduce oxidative stress and inflammation.

Full post here: https://www.reddit.com/r/Penny_Stocks_Canada/comments/1hwu7ud/thiogenesis_therapeutics_corp_ttiv_ttipf/

*Posted on behalf of Thiogenesis Therapeutics Corp.
👍️0
StockInfo11 StockInfo11 1 month ago
Thiogenesis Therapeutics (TTI.v) targets multi-billion dollar markets with its thiol-active compound for mitochondrial dysfunctions, advancing Phase II trials in 2025 for MELAS, Leigh syndrome, and pediatric MASH. Valuation Lab values shares at CAD 7.5, citing strong IP and a cash runway into Q4 2025. Full report here: https://www.valuationlab.com/app/download/8229158562/vL+Thiogenesis+Flash+Update+16DEC24.pdf

*Posted on behalf of Thiogenesis Therapeutics Corp.
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Representing a transformative opportunity in the biotech space, Thiogenesis Therapeutics (TTI.v) is leveraging its innovative thiol-based therapeutic platform to address rare and underserved mitochondrial dysfunction diseases: https://x.com/StckMasterFlash/status/1871347807430291939

Unlike most biotech ventures, TTI’s lead candidate, TTI-0102, targets a well-defined niche in conditions such as MELAS, Leigh Syndrome, and Pediatric MASH—areas with significant unmet needs and little market competition. This focus on orphan drug markets positions the company to benefit from expedited regulatory approval pathways and strong pricing power.
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Offering a groundbreaking investment opportunity with a projected upside of 1130%, Thiogenesis Therapeutics (TTI.v) is driven by its innovative thiol-active compounds targeting rare mitochondrial dysfunction diseases with its lead product, TTI-0102, addressing significant unmet medical needs in conditions like MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH: https://x.com/StckMasterFlash/status/1871347807430291939

With robust patent protection until 2037, TTI has an ambitious pipeline, featuring Phase II trials and regulatory filings set for 2025, positioning it for market launches by 2026-2027 and potential peak sales exceeding CAD 5.6 billion. TTI's strategic focus on orphan drug markets and licensing for broader indications positions the company to capitalize on expedited regulatory pathways with strong intellectual property, focused strategy, and projected market opportunities making it a compelling read for those seeking high-reward biotech investments.
👍️0
Consequent Consequent 1 month ago
Good recap of Thiogenesis Therapeutics Corp. (TTI.v TTIPF) and the development of the drug TTI-0102 which is designed to treat pediatric NASH by releasing cysteamine, a potent antioxidant that can reduce oxidative stress and inflammation.

More on Thiogenesis and the addressable market in the post: https://www.reddit.com/r/CanadianStockExchange/comments/1hs6occ/thiogenesis_therapeutics_corp_ttiv_ttipf/

*Posted on behalf of Thiogenesis Therapeutics Corp.
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Addressing an estimated global market opportunity of CAD 9.8 billion, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech innovating in the treatment of rare mitochondrial diseases, with a focus on high-value orphan indications such as MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH: https://x.com/StckMasterFlash/status/1871347807430291939

At the heart of its pipeline is TTI-0102, a prodrug of cysteamine designed to overcome traditional challenges with dosing and side effects. TTI’s strong intellectual property extending to 2037 and strategic use of expedited regulatory pathways position it as a key player in this niche yet transformative space, offering a compelling high-risk, high-reward opportunity with a risk-adjusted valuation suggesting a potential 1130% upside amid clinical trials beginning in 2025.
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Designed to revolutionize the treatment of rare mitochondrial diseases like MELAS and Leigh Syndrome, Thiogenesis Therapeutics (TTI.v), a clinical-stage biotech company, is advancing TTI-0102, a prodrug designed: https://x.com/StckMasterFlash/status/1871347807430291939

Targeting a market opportunity exceeding CAD 9.8 billion, TTI is positioned for a range of key milestones from multiple Phase II trials in 2025, making the company a compelling high-reward investment with an estimated 1130% upside potential, according to Valuation Lab.
👍️0
CommodityCoverage CommodityCoverage 2 months ago
Clinical-stage biotech company, Thiogenesis Therapeutics (TTI.v), is advancing TTI-0102, a prodrug designed to revolutionize the treatment of rare mitochondrial diseases like MELAS and Leigh Syndrome: https://x.com/StckMasterFlash/status/1871347807430291939

With patent protection until 2037 and a market opportunity exceeding CAD 9.8 billion, the company is positioned for explosive growth. Key milestones, including multiple Phase II trials in 2025, align with an estimated 1130% upside potential, making TTI.v a compelling high-risk, high-reward investment. If you're intrigued by cutting-edge science, rare disease innovation, and significant financial upside, this report is a must-read.
👍️0
CommodityCoverage CommodityCoverage 2 months ago
'A Prodrug for Mito-Dysfunction' Offering 113% Upside Potential - Thiogenesis Therapeutics (TTI.v) Research Report Summary: https://x.com/StckMasterFlash/status/1871347807430291939

Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases including MELAS and Leigh Syndrome (LS). TTI offers a high-risk, high-reward investment opportunity, driven by its innovative approach to treating rare mitochondrial diseases and the potential for substantial market penetration across its targeted indications.
👍️0
CommodityCoverage CommodityCoverage 2 months ago
Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases MELAS and Leigh Syndrome (LS): https://x.com/StckMasterFlash/status/1866620308544786857

MELAS: Phase 2 trial begins in early 2025 (Netherlands & France) targeting 15,000 U.S. and 20,000 EU patients.
Leigh Syndrome: IND filing planned for early 2025 for this severe, untreatable disorder affecting 1 in 40,000 births.
👍️0
CommodityCoverage CommodityCoverage 2 months ago
Yesterday, Thiogenesis Therapeutics (TTI.v) presented significant updates on its two clinical programs that are advancing its lead product, TTI-0102 which aims to address oxidative stress and improve outcomes for rare, debilitating conditions that affect a range of patients worldwide: https://x.com/StckMasterFlash/status/1866620308544786857

Having submitted its Clinical Trial Application Part II in Europe, TTI plans to launch a Phase 2 trial in early 2025 in the Netherlands and France for MELAS, focusing on physical endurance and biomarker analysis in 12 patients. For Leigh Syndrome, TTI collaborated with a leading U.S. children’s hospital and engaged in a pre-IND meeting with the FDA, paving the way for an IND submission and a Phase 2a trial in early 2025.
👍️0
CommodityCoverage CommodityCoverage 2 months ago
Today, Thiogenesis Therapeutics (TTI.v), a clinical-stage biotechnology company, presented updates on its two clinical programs for mitochondrial diseases during the UMDF "Bench-to-Bedside" webcast: https://www.newsfilecorp.com/release/233143/Thiogenesis-Announces-Presentation-on-UMDF-Webcast-Featuring-Clinical-Trials-in-Mitochondrial-Disease

TTI is advancing its lead product, TTI-0102, with promising applications in treating MELAS, a rare disorder affecting 15,000 patients in the U.S. and 20,000 in the EU, and Leigh Syndrome (LS), which is diagnosed in infancy and affects 1 in 40,000 births (More info: https://www.reddit.com/r/RichTogether/comments/1gvx18y/with_45m_in_the_bank_a_low_burn_rate_strong/)
👍️0
CommodityCoverage CommodityCoverage 2 months ago
Last week, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v) announced attaining DTC eligibility in the US, facilitating electronic settlement of its common shares; a significant milestone aligning with the company's plans for a future U.S. listing: https://www.newsfilecorp.com/release/231667/Thiogenesis-Announces-DTC-Eligibility-in-the-U.S.-and-Other-Updates 

Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, TTI is focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases -  a substantial addressable market as mitochondrial diseases collectively affect millions worldwide, with very few effective therapies currently available: https://x.com/StckMasterFlash/status/1859742853578076171
👍️0
CommodityCoverage CommodityCoverage 3 months ago
Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, Thiogenesis Therapeutics (TTI.v) is a biopharmaceutical company focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases: https://drive.google.com/file/d/1Obahg9CXnD__6WbReUT93Sgzu6C9EoD_/view

Representing a growing market segment in the pharmaceutical industry, estimates suggest the mitochondrial disease therapies market to be worth USD 1,817 million by 2030. Thus,

By leveraging its innovative compounds and focusing on pediatric diseases with no approved therapies, TTI has the potential to make significant strides in addressing critical gaps alongside addressing multiple indications within this growing market, presenting significant commercial and therapeutic opportunities.
👍️0
CommodityCoverage CommodityCoverage 3 months ago
Insightful breakdown of Thiogenesis Therapeutics (TTI.v) and the market opportunity its taking advantage of by focusing on pediatric diseases with unmet medical needs including pediatric NASH which currently has zero approved drugs or treatments: https://x.com/airic101/status/1856816752128143615
👍️0
CommodityCoverage CommodityCoverage 3 months ago
Targeting a large addressable market in developing therapeutic compounds for pediatric diseases with unmet medical needs, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company: https://x.com/StckMasterFlash/status/1856131383535542718

Notably, TTI recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction, which complements the companys previous patent approvals in the US and Japan, as well as aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.
👍️0
CommodityCoverage CommodityCoverage 3 months ago
Developing therapeutic compounds for pediatric diseases with unmet medical needs and a large addressable market, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v), recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction: https://x.com/StckMasterFlash/status/1856131383535542718

Complementing previous patent approvals in the US and Japan, the IP protection aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.
👍️0